The therapeutic application of Cordipin SR generally helps manage symptoms and may provide sustained support across two primary chronic cardiovascular domains: high blood pressure and chest pain. This sustained-release formulation is relevant in clinical settings requiring consistent, long-term symptomatic assistance to support functional stability.

The medication is commonly used for the management of high blood pressure and is relevant for the treatment of angina.

---

Sustained Control for Essential Hypertension

This therapeutic application is commonly used for conditions marked by the persistent systemic imbalance of Essential Hypertension (high blood pressure). The medication is applied to help manage elevated arterial pressure readings, which contributes to easing the overall symptom load on the circulatory system and may be part of symptomatic management that supports long-term circulatory function.

Easing the Burden of Anginal Chest Pain

Cordipin SR plays a role in managing symptoms related to Angina Pectoris, including both chronic stable and vasospastic forms. It is relevant in situations where patients experience recurrent or effort-induced symptoms of chest discomfort. This use assists with maintaining functional stability by assisting with the reduction of the intensity and occurrence of anginal episodes, supporting the patient during symptomatic periods.

Supportive Management of Peripheral Vasospasm

The medication is also considered relevant across domains where additional symptomatic support is needed for conditions involving peripheral vasospasm, such as Raynaud's Phenomenon. It is applied in addressing symptoms that interfere with daily functioning, such as numbness or discoloration in the extremities, to support blood flow and is relevant for easing the discomfort.

Quick Fact: Supports management of symptomatic strain linked to high blood pressure and chronic chest pain.

---

The medication is used to help manage symptoms associated with Essential Hypertension, Chronic Stable Angina, Vasospastic Angina, and certain Peripheral Vasospastic Disorders.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile: Who Can and Cannot Use Cordipin SR

Official regulatory information defines the eligibility for Cordipin SR (nifedipine sustained-release) primarily through a list of contraindicated populations and conditions, with an emphasis on patient safety and formulation-specific limitations.

Populations that Must Not Use Cordipin SR (Contraindications):

• Individuals with known hypersensitivity or allergy to nifedipine or any related dihydropyridine compound.
• Patients experiencing acute cardiovascular instability, specifically those in cardiogenic shock or with unstable angina.
• Women who are pregnant or who may become pregnant, due to documented risk.
• Individuals with a significant mechanical obstruction in the gastrointestinal tract (such as a Kock pouch) which may interfere with the sustained-release mechanism.
• Use during the first month following a myocardial infarction (heart attack).

Populations Requiring Special Consideration or for Whom Use is Not Recommended:

• Pediatric population: Safety and efficacy have not been established for patients under 18 years of age.
• Lactating women: Use is not recommended as nifedipine is excreted into breast milk.
• Patients with severe hepatic impairment (liver disease) should be closely monitored, and dose adjustment may be necessary.

Patients should always consult with a healthcare provider to ensure that none of these exclusions apply before starting treatment.

Cordipin SR (nifedipine) is primarily metabolized in the liver by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway is the basis for most clinically significant drug interactions.

Interactions Causing Increased Nifedipine Levels

Co-administration with strong CYP3A4 inhibitors can significantly increase the concentration and systemic exposure of nifedipine. Examples of these inhibitors include certain macrolide antibiotics (like clarithromycin), azole antifungals (like ketoconazole), and HIV protease inhibitors. The ulcer medication cimetidine is also documented to increase nifedipine's peak plasma concentration and overall exposure.

Interactions Causing Decreased Nifedipine Levels

Conversely, co-administration with strong CYP3A4 inducers, such as the antibiotic rifampin or certain anticonvulsants (like phenytoin and carbamazepine), is contraindicated. These drugs drastically increase the clearance of nifedipine, leading to inadequate blood levels and a potential loss of therapeutic effect.

Other Important Drug and Food Interactions

• Digoxin: Nifedipine can increase the plasma concentrations of digoxin; therefore, digoxin levels should be monitored when initiating, adjusting, or discontinuing nifedipine therapy.
• Beta-Blockers and other Antihypertensives: Co-administration may enhance the blood pressure-lowering effect, requiring close clinical monitoring for severe hypotension.
• Grapefruit Juice: Ingestion of grapefruit or grapefruit juice must be avoided as it inhibits intestinal CYP3A4, resulting in substantially increased nifedipine exposure.

How Cordipin SR Works

Cordipin SR (nifedipine) operates solely through pharmacodynamic action, establishing a clear link between its molecular target and its systemic effects by regulating vascular muscle tone.

---

Selective Calcium Channel Blockade

The drug acts as an inhibitor on the L-type voltage-gated calcium channels (Cav1.2) found on vascular smooth muscle cells. By preventing the influx of extracellular calcium ions (Ca^2+), the drug suppresses the key molecular trigger for muscle contraction, which is the fundamental step in reducing vascular resistance.

---

Regulation of Systemic Vascular Resistance

This mechanism leads to widespread peripheral arterial vasodilation and a reduction in the Systemic Vascular Resistance (SVR). This systemic effect directly decreases the cardiac afterload—the mechanical resistance the heart must overcome—which subsequently modulates the myocardial oxygen supply and demand ratio by decreasing oxygen demand and increasing oxygen delivery.

---

⏱️ Mechanism-Dependent Attenuation

This cluster addresses the specific physiological characteristic of the sustained-release (SR) formulation, which controls the delivery rate to controls the rate of resistance reduction, thereby attenuating the intensity of triggering the reflex sympathetic activation (a mechanism that causes compensatory physiological responses like increased heart rate) typically seen with immediate-release agents.

How to Use Cordipin SR

Cordipin SR is an oral Sustained-Release tablet that is used according to established administration protocols. This section summarizes standard administration guidelines without discussing therapeutic benefits or safety information.

Official Dosing and Frequency

Feature	Official Instruction Summary
Route of Administration	Oral (swallowed)
Frequency	Once Daily
Starting Dose	Typically 30 mg to 60 mg per day
Maximum Dose	Up to 120 mg per day

Essential Administration Steps

1. Swallow the Tablet Whole: To ensure the proper sustained release of the active ingredient, the tablet must not be broken, crushed, chewed, or divided before intake. This is a requirement for the integrity of Nifedipine Sustained-Release delivery systems.
2. Dose Adjustment: Changes to the dose are typically made gradually, with at least 7 to 14 days between dose increases, to monitor the response to the adjusted regimen.
3. Dietary Restriction: Consumption of grapefruit or grapefruit juice is avoided while using this medication.

Population-Specific Guidance

Consideration is given to the need for monitoring when prescribing to older adults (aged 65 years and over) or those with hepatic impairment, as these groups may require careful observation and potentially lower maintenance doses. For patients with renal impairment, dose adjustments are typically not required.

Evidence for Use in High Blood Pressure (Essential Hypertension)

Research primarily involves Randomized Controlled Trials (RCTs) and systematic reviews examining sustained-release Nifedipine in adult populations with mild to moderate hypertension. Studies monitor changes in Systolic and Diastolic Blood Pressure (BP), focusing on the consistency of these changes over the 24 -hour dosing period. Long-term studies for related formulations have tracked major endpoints like cardiovascular events. The evidence structure primarily includes patients with mild to moderate conditions; data for groups with severely elevated or complex hypertension is limited.

---

Evidence for Use in Chronic Chest Pain (Chronic Stable Angina)

Research includes RCTs and meta-analyses exploring short-term symptom changes in adult patients with effort-associated chest pain. Studies examine outcomes related to physical discomfort, such as the frequency of anginal episodes and changes in exercise tolerance on standardized tests. Follow-up durations were typically limited (several weeks to a few months), meaning the long-term evidence structure for antianginal use is more limited than for blood pressure management.

---

Research on Vasospastic Conditions (Angina and Peripheral Vasospasm)

Research has explored Nifedipine in the context of conditions like Vasospastic Angina and Peripheral Vasospasm (Raynaud’s Phenomenon). The evidence structure relies on smaller-scale clinical studies and reports, examining the frequency of vasospastic episodes and changes in reported pain or discoloration. The evidence for these uses is limited; sample sizes were modest, and the research is often preliminary.

---

Evidence Gaps and Areas for Future Research

Long-term outcomes are not fully established for every indication. Data for certain groups, such as pediatric patients or those with complex comorbidities, remain insufficient. Research is ongoing, and findings have sometimes been mixed when comparing different sustained-release formulations of Nifedipine.

Key Studies & References

1. Nifedipine (Extended-Release): Drug Information (NIH/MedlinePlus)
2. Nifedipine (Oral Route): Drug Information (NIH/MedlinePlus)

Common questions about Cordipin SR (FAQ)

Q: Do I need to take Cordipin SR with food?

A: Official information indicates that many sustained-release nifedipine products can be taken either with a meal or without food. To ensure you are following the correct administration method, it is important to adhere to the guidance provided in the official product labeling for that specific formulation.

Q: What happens if I miss a dose of Cordipin SR?

A: If a dose is forgotten, official guidance typically states that the dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is resumed. Regulatory documents caution against taking a double dose to make up for a missed one.

Q: Are there any common over-the-counter medications that interact with Cordipin SR?

A: Cordipin SR is processed by an enzyme system in the liver called CYP3A4. Because many common over-the-counter (OTC) medications, supplements, and vitamins can affect this enzyme, there is a risk of altering the concentration of Cordipin SR in your blood. Therefore, patients are advised to discuss all products, including OTC drugs, with a healthcare provider or pharmacist before use.

Q: Does Cordipin SR have known interactions with alcohol?

A: Official safety information advises caution regarding alcohol consumption while taking Cordipin SR. Alcohol can potentially enhance the blood pressure-lowering effect of the medication. This additive effect can increase the risk of side effects such as lightheadedness, dizziness, or fainting. Caution is generally noted in official information regarding the use of alcohol, especially when beginning treatment or adjusting the dosage.

Q: Is Cordipin SR safe to use for people with kidney problems?

A: According to regulatory documents, the way Cordipin SR is eliminated from the body means that its metabolism is usually not significantly affected by kidney impairment. However, some changes in kidney function tests have been rarely reported in individuals with pre-existing kidney conditions. Official guidelines recommend that patients with kidney problems receive appropriate monitoring by a healthcare provider.

Q: Do people usually take Cordipin SR long-term?

A: Official documentation indicates that Cordipin SR is typically prescribed for the long-term management of chronic conditions such as high blood pressure and stable angina. Treatment may be continued indefinitely, based on the patient's ongoing condition and the judgment of the prescribing healthcare professional.

Q: Is Cordipin SR available as a generic medicine?

A: Yes, the active ingredient in Cordipin SR, which is nifedipine sustained-release, is widely available in many countries as a generic medicine. Generic versions are required by regulatory bodies to meet the same quality and effectiveness standards as the brand-name product.

Q: What is the shelf life of Cordipin SR tablets?

A: The exact shelf life of Cordipin SR is determined by the manufacturer and is clearly marked on the packaging. Official instructions require that the expiry date printed on the packaging be checked, and the medication must not be used beyond that date to maintain its stability.

Q: Is fatigue a common side effect when starting Cordipin SR?

A: Official safety data lists fatigue, weakness, and feeling unwell (asthenia) as common side effects of nifedipine sustained-release formulations. This means these effects occur in approximately 1% to 10% of patients. Official safety information notes that side effects often occur more frequently when treatment is first initiated.

Q: Will Cordipin SR interact with my cholesterol medication?

A: Yes, regulatory documents note that nifedipine can potentially increase the blood concentrations of certain cholesterol-lowering medications, specifically some statins (HMG-CoA reductase inhibitors). If this combination is used, co-administration with certain statins may require clinical monitoring to manage any increased risk of side effects.

Q: Will Cordipin SR interfere with common herbal supplements?

A: Regulatory warnings specifically highlight that the herbal supplement St. John’s Wort can significantly interfere with Cordipin SR. This supplement can cause the body to clear the medication too quickly, leading to inadequate blood levels and loss of therapeutic effect. It is important that patients discuss all herbal products with a healthcare provider due to the potential for interaction.

Q: Does stopping Cordipin SR suddenly cause any issues?

A: Official safety warnings advise against abruptly stopping Cordipin SR after taking it for a long period, especially for patients with existing heart conditions. Sudden discontinuation has been reported to cause a sharp increase in blood pressure or a return or worsening of angina symptoms. Official safety information states that treatment must be discontinued gradually under the direction of a healthcare professional.

Q: What kinds of foods or supplements should be avoided while on Cordipin SR?

A: Regulatory documents consistently note that the consumption of grapefruit or grapefruit juice should be avoided. Ingesting grapefruit can significantly increase the amount of nifedipine absorbed into your blood, potentially increasing the risk of adverse effects. Otherwise, official documents do not list restrictions for other common foods.

Q: Is Cordipin SR known to cause weight changes?

A: While Cordipin SR itself does not directly cause significant weight gain, a very common side effect is peripheral oedema (swelling in the hands or feet). This fluid retention may be reflected as a change on the scale. Unusual weight changes are also documented as a less frequent adverse effect.

Q: Does Cordipin SR have to be taken at the exact same time every day?

A: Since Cordipin SR is a sustained-release medication taken once daily, official instructions indicate that the tablet should be taken at approximately 24-hour intervals. This helps ensure a consistent and steady level of the active drug in the body throughout the day and night.

Q: Are there any known severe side effects of Cordipin SR I should be aware of?

A: Official safety documentation highlights that serious adverse reactions, although rare, include severe allergic reactions (e.g., swelling of the face or throat), severe drops in blood pressure (hypotension), and in some cases, a worsening of angina (chest pain) when treatment is initiated or the dose is increased. If any severe side effects are experienced, regulatory documents advise patients to seek immediate medical attention or report them to a healthcare provider.

How to Store and Dispose of Cordipin SR?

The storage and disposal of Cordipin SR (Nifedipine Sustained-Release) must strictly adhere to the requirements outlined in official regulatory labeling to maintain product stability and ensure public safety.

Official Storage Requirements

Classification	Requirement
Temperature	Store at controlled room temperature (15 C to 30 C). Do not store above 30 C or freeze.
Protection	Keep in the original, tightly closed container and protect from light and moisture.
Safety/Stability	Keep out of the sight and reach of children. Do not use after the expiry date printed on the carton.

Disposal Instructions

Official instructions require that expired or unused Cordipin SR must not be thrown away in household waste or via wastewater (e.g., flushed down the toilet). The medication must be disposed of according to local/regional/national regulations, typically by returning it to a pharmacist for proper pharmaceutical waste disposal.